2026
article
OpenAlex
Susan Alford, Sheena K. Aurora, Justine Coppinger, Marti Jimenez-Mausbach et autres
To uncover primary care physicians’ (PCPs’) attitudes on, perceptions of and barriers to Alzheimer’s disease (AD) diagnosis and incorporating blood biomarkers (BBMs) into the diagnostic workflow.
gb, us, dk, pt
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
J.B. Burns, Susan Alford, Justine Coppinger, Martí Jiménez‐Mausbach et autres
INTRODUCTION: We aimed to explore primary care physicians' (PCP) attitudes, perceptions, and barriers toward Alzheimer's disease (AD) diagnosis and incorporating blood biomarker (BBM) tests into the diagnostic workflow. METHODS: Remote 60-min interviews with 20 PCPs were conducted (May 2023). Participants included generalists …
us, dk, pt
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Nicole R. Fowler, Sutapa Ray, Deanna R. Willis, Dustin B. Hammers et autres
Abstract INTRODUCTION Blood biomarker (BBM) tests could improve early detection of Alzheimer's disease (AD), but their acceptability and feasibility in primary care (PC) are unclear. METHODS A BBM for AD pathology was offered to patients who screened positive for cognitive impairment in …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Susan Alford, Sheena K. Aurora, Justine Coppinger, Martí Jiménez‐Mausbach et autres
BACKGROUND: Early and accurate diagnosis of Alzheimer's disease (AD) is critical for ensuring access to targeted lifestyle recommendations and disease modifying therapies (DMT), which can slow disease progression. Historically, diagnosis has been slow, complex, costly, inaccurate, and inconsistent, with individuals often diagnosed …
us, dk, pt
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Mark Monane, Kim G. Johnson, Darren R. Gitelman, Lawren A. VandeVrede et autres
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. However, implementation of AD blood …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Justine Coppinger, Tim West, Kris M. Kirmess, Ilana Fogelman et autres
The diagnostic performance of the Amyloid Probability Score 2 (APS2; the algorithmic result of the PrecivityAD2™ blood test) was originally trained and validated in two cohorts of cognitively impaired (CI) individuals and is in clinical use. Here, we further test the repeatability …
us
(code pays fourni par la source)
2025
article
OpenAlex
Sheena K. Aurora, Justine Coppinger, Sutapa Ray, Joel B. Braunstein et autres
To analyze real-world HCP utilization of a high performing Alzheimer’s disease (AD) blood biomarker (BBM) test.
us
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Justine Coppinger, Tim West, Kris M. Kirmess, Ilana Fogelman et autres
Objective: blood test - was originally trained and validated in two cohorts of cognitively impaired (CI) individuals. Using an independent cohort to evaluate blood test reliability, we conducted an external diagnostic accuracy assessment of the validated APS2 cut point as it is …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Valeria Baldivieso, Kirk I. Erickson, Steven R. Smith, Richard E. Pratley et autres
Abstract Background Early identification of Alzheimer’s disease (AD) is critical for disease‐modifying therapies. The Davos Alzheimer’s Collaborative flagship program tested the feasibility of implementing a digital cognitive assessment (DCA) followed by a blood biomarker (BBM) for early detection of cognitive impairment (CI). …
us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Mark Monane, Kim G. Johnson, B. Joy Snider, Raymond Scott Turner et autres
OBJECTIVE: The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (PrecivityAD® blood test) in symptomatic patients evaluated for Alzheimer's …
us
(code pays fourni par la source)
2022
article
OpenAlex
Tim MacLeod, Magda R. Baksh, Otelo Corrêa dos Santos Filho, Ishtar Govia et autres
Abstract Background Blood‐based biomarker tests are critical tools with the potential to change pathways for dementia diagnosis and care. These tests are less invasive than PET scan or lumbar puncture, potentially more affordable, and thus more accessible across more care settings and …
ca, us, jm, mx, jp, gb
(code pays fourni par la source)
Accès ouvert
2016
preprint
OpenAlex
Janet Malcolmson, Robert S. Kleyner, David H. Tegay, W. Y. Adams et autres
The SCN8A gene encodes the sodium voltage-gated channel alpha subunit 8. Mutations in this gene have been associated with early infantile epileptic encephalopathy type 13. With the use of whole-exome sequencing, a de novo missense mutation in SCN8A was identified in a …
us
(code pays fourni par la source)